Description
IGF-DES Technical Overview
IGF-DES, also known as Des(1-3)IGF-I, is a truncated form of insulin-like growth factor 1 (IGF-1). The compound lacks the first three N-terminal amino acid residues—Gly-Pro-Glu—present in mature human IGF-1.
Removal of these residues produces a 67-amino-acid peptide that retains structural features associated with IGF-1 receptor signaling while exhibiting reduced binding to certain insulin-like growth factor binding proteins (IGFBPs).
Des(1-3)IGF-I has been investigated in experimental research involving IGF-1 receptor activation, cellular proliferation, tissue growth, and growth factor-binding protein interactions.
Published studies have reported increased biological activity in selected experimental systems compared with full-length IGF-1. These findings are model-dependent and do not establish superior clinical effectiveness or safety.
Compound Specifications
| Property | Value |
|---|---|
| Compound Name | IGF-DES |
| Alternative Names | Des(1-3)IGF-I, Des-IGF-1 |
| CAS Number | 112603-35-7 |
| Parent Molecule | Insulin-like Growth Factor 1 |
| Sequence Length | 67 amino acid residues |
| Structural Modification | Deletion of the first three N-terminal residues of IGF-1 |
| Deleted Residues | Gly-Pro-Glu |
| Peptide Classification | Truncated IGF-1 analogue |
| Primary Research Receptor | IGF-1R |
| Research Category | Growth Factor Research |
| Vial Content | 2mg |
Compound identity should be confirmed using the complete 67-residue sequence, disulfide connectivity, and batch-specific analytical documentation. The listed specifications refer to Des(1-3)IGF-I rather than IGF-1 LR3 or full-length IGF-1.
Storage and Handling
- Store according to the manufacturer’s validated stability recommendations.
- Protect the protein from moisture and unnecessary light exposure.
- Avoid repeated temperature fluctuations.
- Follow handling procedures appropriate for disulfide-containing growth factor proteins.
- Confirm formulation-specific stability using manufacturer documentation.
Lyophilized Format
IGF-DES may be manufactured as a lyophilized protein preparation.
Freeze-drying can support protein stability, although stability depends on formulation, moisture exposure, temperature, and molecular integrity.
The physical form and storage conditions of the specific preparation require manufacturer confirmation.
Research Use Disclaimer
IGF-DES is an experimental research compound and is not FDA-approved for human therapeutic use.
It is not intended for human or veterinary administration, clinical applications, or diagnostic procedures.
Frequently Asked Questions
What Is IGF-DES 2mg?
IGF-DES 2mg is a research preparation of Des(1-3)IGF-I, a 67-amino-acid form of insulin-like growth factor 1.
How Does IGF-DES Differ From IGF-1?
IGF-DES lacks the first three amino acids of mature IGF-1, resulting in altered interactions with certain IGF-binding proteins.
What Is the CAS Number?
The CAS number for Des(1-3)IGF-I is 112603-35-7.
What Research Areas Involve IGF-DES?
Research includes IGF-1 receptor signaling, cell proliferation, growth factor binding proteins, and tissue growth mechanisms.
Is IGF-DES the Same as IGF-1 LR3?
No. IGF-DES and IGF-1 LR3 are structurally distinct modified forms of IGF-1.
Research Overview
Des(1-3)IGF-I was characterized as a naturally occurring truncated form of IGF-1. Research has investigated its reduced binding to selected IGF-binding proteins and the resulting differences in biological activity.
A review published in 1996 reported that Des(1-3)IGF-I demonstrated substantially greater activity than IGF-I in selected cultured cell growth assays. The authors attributed this difference primarily to reduced interactions with IGF-binding proteins.
IGF-1 Receptor Research
IGF-DES has been investigated in experiments involving IGF-1R-associated signaling pathways and cellular responses to growth factors.
IGF-Binding Protein Research
Removal of the first three IGF-1 residues changes binding interactions with certain IGF-binding proteins, making Des(1-3)IGF-I relevant to studies of growth factor bioavailability.
Cellular Proliferation Research
Experimental investigations have compared proliferative responses to full-length IGF-1 and its truncated derivatives in cultured cells.
Tissue Growth Research
Animal and cellular studies have explored the activity of Des(1-3)IGF-I in tissue growth models. These experimental findings do not establish safe or effective applications in humans.
Research Applications
| Research Area | In Vitro Application |
|---|---|
| IGF-1R Signaling | Growth factor receptor signaling assays |
| IGF-Binding Proteins | Protein interaction and binding studies |
| Cell Proliferation | Growth factor response measurements |
| Protein Structure | Truncated growth factor characterization |
References
- Ballard FJ, Wallace JC, Francis GL, Read LC, Tomas FM. (1996). Des(1-3)IGF-I: A Truncated Form of Insulin-Like Growth Factor-I. International Journal of Biochemistry & Cell Biology. PubMed PMID: 8930132.
Certificate of Analysis (COA)
Researchers should verify the full protein sequence, disulfide connectivity, identity, purity, and actual content using batch-specific analytical documentation.
For information about available documentation, contact Peptide Lives.
Reviews
There are no reviews yet.